SER Fundamental Analysis - SERINA THERAPEUTICS INC.

Fundamental Rating

Overall SER gets a fundamental rating of 2 out of 10. We evaluated SER against 542 industry peers in the Biotechnology industry. SER scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SER is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

SER had negative earnings in the past year.

In the past year SER has reported a negative cash flow from operations.

SER had negative earnings in each of the past 5 years.

In the past 5 years SER always reported negative operating cash flow.

1.2 Ratios

SER has a worse Return On Assets (-124.61%) than 81.18% of its industry peers.

SER has a worse Return On Equity (-618.26%) than 79.34% of its industry peers.

		Industry Rank	Sector Rank
ROA	-124.61%
ROE	-618.26%
ROIC	N/A

ROA(3y)-204.08%

ROA(5y)-232.88%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SER so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SER does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for SER has been increased compared to 1 year ago.

SER has less shares outstanding than it did 5 years ago.

SER has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

SER has an Altman-Z score of -10.01. This is a bad value and indicates that SER is not financially healthy and even has some risk of bankruptcy.

SER has a worse Altman-Z score (-10.01) than 72.32% of its industry peers.

SER has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-10.01

ROIC/WACCN/A

WACC9.68%

2.3 Liquidity

SER has a Current Ratio of 2.24. This indicates that SER is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 2.24, SER is doing worse than 72.32% of the companies in the same industry.

SER has a Quick Ratio of 2.24. This indicates that SER is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of SER (2.24) is worse than 69.93% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.24
Quick Ratio	2.24

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.97% over the past year.

Looking at the last year, SER shows a very negative growth in Revenue. The Revenue has decreased by -60.56% in the last year.

Measured over the past years, SER shows a very negative growth in Revenue. The Revenue has been decreasing by -49.65% on average per year.

EPS 1Y (TTM)88.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-205.45%

Revenue 1Y (TTM)-60.56%

Revenue growth 3Y-26.32%

Revenue growth 5Y-49.65%

Sales Q2Q%154.9%

3.2 Future

Based on estimates for the next years, SER will show a small growth in Earnings Per Share. The EPS will grow by 4.65% on average per year.

SER is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.

EPS Next Y-15.08%

EPS Next 2Y-5.39%

EPS Next 3Y4.65%

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SER. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.39%

EPS Next 3Y4.65%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SER!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SERINA THERAPEUTICS INC.

NYSEARCA:SER (9/5/2025, 8:04:00 PM)

After market: 5 -0.09 (-1.77%)

5.09

-0.19 (-3.6%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-11 2025-08-11/amc

Earnings (Next)11-10 2025-11-10

Inst Owners3.4%

Inst Owner Change23.04%

Ins Owners18.75%

Ins Owner Change40.94%

Market Cap52.17M

Analysts80

Price Target13.26 (160.51%)

Short Float %0.97%

Short Ratio0.26

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-16%

Min EPS beat(2)-53.76%

Max EPS beat(2)21.75%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)18.18%

EPS NQ rev (1m)-8.43%

EPS NQ rev (3m)N/A

EPS NY rev (1m)11.54%

EPS NY rev (3m)11.54%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	931.65
P/FCF	N/A
P/OCF	N/A
P/B	28.95
P/tB	28.95
EV/EBITDA	N/A

EPS(TTM)-1.51

EYN/A

EPS(NY)-1.68

Fwd EYN/A

FCF(TTM)-1.53

FCFYN/A

OCF(TTM)-1.52

OCFYN/A

SpS0.01

BVpS0.18

TBVpS0.18

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-124.61%
ROE	-618.26%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-204.08%

ROA(5y)-232.88%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	37.24%
Cap/Sales	96.43%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.24
Quick Ratio	2.24
Altman-Z	-10.01

F-Score3

WACC9.68%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)88.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-205.45%

EPS Next Y-15.08%

EPS Next 2Y-5.39%

EPS Next 3Y4.65%

EPS Next 5YN/A

Revenue 1Y (TTM)-60.56%

Revenue growth 3Y-26.32%

Revenue growth 5Y-49.65%

Sales Q2Q%154.9%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5YN/A

EBIT growth 1Y-71.16%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-143.43%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-142.59%

OCF growth 3YN/A

OCF growth 5YN/A

SERINA THERAPEUTICS INC. (SER) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens